» Articles » PMID: 23954159

Fusobacterium Nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-immune Microenvironment

Abstract

Increasing evidence links the gut microbiota with colorectal cancer. Metagenomic analyses indicate that symbiotic Fusobacterium spp. are associated with human colorectal carcinoma, but whether this is an indirect or causal link remains unclear. We find that Fusobacterium spp. are enriched in human colonic adenomas relative to surrounding tissues and in stool samples from colorectal adenoma and carcinoma patients compared to healthy subjects. Additionally, in the Apc(Min/+) mouse model of intestinal tumorigenesis, Fusobacterium nucleatum increases tumor multiplicity and selectively recruits tumor-infiltrating myeloid cells, which can promote tumor progression. Tumors from Apc(Min/+) mice exposed to F. nucleatum exhibit a proinflammatory expression signature that is shared with human fusobacteria-positive colorectal carcinomas. However, unlike other bacteria linked to colorectal carcinoma, F. nucleatum does not exacerbate colitis, enteritis, or inflammation-associated intestinal carcinogenesis. Collectively, these data suggest that, through recruitment of tumor-infiltrating immune cells, fusobacteria generate a proinflammatory microenvironment that is conducive for colorectal neoplasia progression.

Citing Articles

Gut microbiota therapy in gastrointestinal diseases.

Ullah H, Arbab S, Chang C, Bibi S, Muhammad N, Rehman S Front Cell Dev Biol. 2025; 13:1514636.

PMID: 40078367 PMC: 11897527. DOI: 10.3389/fcell.2025.1514636.


Emerging roles of intratumoral microbiota: a key to novel cancer therapies.

Fang P, Yang J, Zhang H, Shuai D, Li M, Chen L Front Oncol. 2025; 15:1506577.

PMID: 40071093 PMC: 11893407. DOI: 10.3389/fonc.2025.1506577.


Integrated spatial multi-omics profiling of Fusobacterium nucleatum in breast cancer unveils its role in tumour microenvironment modulation and cancer progression.

Zhao F, An R, Ma Y, Yu S, Gao Y, Wang Y Clin Transl Med. 2025; 15(3):e70273.

PMID: 40070022 PMC: 11897063. DOI: 10.1002/ctm2.70273.


Dietary fibre counters the oncogenic potential of colibactin-producing Escherichia coli in colorectal cancer.

Thakur B, Malaise Y, Choudhury S, Neustaeter A, Turpin W, Streutker C Nat Microbiol. 2025; .

PMID: 40033140 DOI: 10.1038/s41564-025-01938-4.


Blood metabolites reflect the effect of gut microbiota on differentiated thyroid cancer: a Mendelian randomization analysis.

Zhang H, Li Y, Li L BMC Cancer. 2025; 25(1):368.

PMID: 40022019 PMC: 11869591. DOI: 10.1186/s12885-025-13598-y.


References
1.
Josefowicz S, Lu L, Rudensky A . Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012; 30:531-64. PMC: 6066374. DOI: 10.1146/annurev.immunol.25.022106.141623. View

2.
Hayden M, Ghosh S . NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012; 26(3):203-34. PMC: 3278889. DOI: 10.1101/gad.183434.111. View

3.
Garrett W, Lord G, Punit S, Lugo-Villarino G, Mazmanian S, Ito S . Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell. 2007; 131(1):33-45. PMC: 2169385. DOI: 10.1016/j.cell.2007.08.017. View

4.
Castellarin M, Warren R, Freeman J, Dreolini L, Krzywinski M, Strauss J . Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2011; 22(2):299-306. PMC: 3266037. DOI: 10.1101/gr.126516.111. View

5.
Jobin C . Colorectal cancer: CRC--all about microbial products and barrier function?. Nat Rev Gastroenterol Hepatol. 2012; 9(12):694-6. PMC: 3612125. DOI: 10.1038/nrgastro.2012.220. View